Compare Centratama Telekomunikasi Indonesia Tbk. (CENT) vs Dharma Polimetal Tbk. (DRMA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centratama Telekomunikasi Indonesia Tbk. vs Dharma Polimetal Tbk. — how do they compare? Centratama Telekomunikasi Indonesia Tbk. trades at Rp74 (market cap 2.34T, 535.2K 24h volume), while Dharma Polimetal Tbk. trades at Rp930 (market cap 4.35T, 825.7K 24h volume). The key difference: Dharma Polimetal Tbk. is the larger of the two by market cap, and Dharma Polimetal Tbk. is more actively traded (825.7K versus 535.2K). Which is the better fit depends on your goals.
| CENT | DRMA | |
|---|---|---|
Market Cap | 2.34T | 4.35T |
Volume | 535.2K | 825.7K |
Lot | 5.35K | 8.26K |
Turnover | 39.66M | 768.05M |
Average Price | 74.1 | 930.18 |
Value | 39.66M | 768.05M |
Indicative Equilibrium Price | 74 | 930 |
Indicative Equilibrium Volume | 527 | 2 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centratama Telekomunikasi Indonesia Tbk.
PT Centratama Telekomunikasi Indonesia Tbk formerly Centrin Online The corporate was established on February 11th 1987 in Bandung as PT. Centrindo Utama. Since the first establishment, corporate focus the business on the information technology. Start the operation in computer hardware sales such as supporting hardware and monitor which produced by PT. Central Rama Informatiko as a affiliated company. And start the internet service provider business on 1996.
Read more on CENT →About Dharma Polimetal Tbk.
PT Dharma Polimetal Tbk (“the Company”) was established in the Republic of Indonesia on 27 March based on Notarial deed No. 74 of Rukmasanti Hardjasatya, S.H. The Company begin opertions on year 1989 and commenced its commercial activities since 1990. The Company’s Majority shareholder is PT Dharma Inti Anugerah, established in Republic Indonesia on 20 November 2003.
Read more on DRMA →
